Connect with us

News

CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26

gbafNews28

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIP) voted to recommend HPV vaccination with GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) based on shared clinical decision making for individuals 27 through 45 years of age who are not adequately vaccinated. The ACIP also voted to expand routine and catch-up recommendations for males through 26 years of age who are not adequately vaccinated. The CDC currently recommends routine vaccination of females and males 11-12 years of age, and vaccination can begin at age 9. If approved by the CDC, GARDASIL 9 recommendations would be expanded to include females and males 13-26 years of age who have not previously been vaccinated, and for adults 27-45 years of age the decision to vaccinate would be made between an individual and their healthcare provider.

Details of the ACIP recommendations for GARDASIL 9 will be available from the CDC. The provisional recommendations are reviewed by the director of the CDC and the Department of Health and Human Services and final recommendations will become official when published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

GARDASIL 9 is indicated for use in females aged 9-45 for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11. GARDASIL 9 is also indicated for use in males aged 9-45 for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11.

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant].

In the U.S., almost half of new HPV infections occur in adults 25 years of age or older. Approximately 23,000 Americans are diagnosed with cervical, vaginal, vulvar, and anal cancers associated with HPV every year, according to latest published incidence from 2015. The nine types of HPV covered in GARDASIL 9 cause the majority of HPV-related cancers and other diseases in women and men. Even though adults may have already been exposed to some types of HPV covered by the vaccine, GARDASIL 9 may help protect against certain cancers and diseases caused by any of the nine HPV types to which someone has not yet been exposed.

With more than a 100-year legacy in vaccines, Merck is deeply passionate about impacting public health through providing our broad portfolio of vaccines to people around the world, said Dr. Richard M. Haupt, vice president and head of vaccines and infectious diseases, Global Medical Affairs at Merck. We applaud the ACIP and the CDC for their continued efforts to address the significant burden of HPV-related cancers by continuously evaluating vaccination recommendations utilizing a comprehensive body of scientific evidence.

About the ACIP and CDC recommendations

The ACIP develops written recommendations for the routine administration of vaccines to children and adults. The ACIP, which consists of 15 experts in immunization and related fields, provides advice to assist the CDC and the nation in reducing the incidence of diseases that may be prevented with vaccines and to increase the safe usage of vaccines and related biological products. The CDC reviews advice from the ACIP and publishes final recommendations in the MMWR. The Affordable Care Act (ACA) generally requires coverage for all vaccines administered in accordance with final CDC recommendations. This requirement applies to all non-grandfathered commercial plans and Medicaid expansion beneficiaries. Individuals, or their healthcare providers, should contact their health insurance plan to determine vaccine coverage and reimbursement requirements as well as adoption timeframes.

Important information about GARDASIL 9

GARDASIL 9 does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Recipients of GARDASIL 9 should not discontinue anal cancer screening if it has been recommended by a health care professional.

GARDASIL 9 has not been demonstrated to provide protection against diseases from vaccine HPV types to which a person has previously been exposed through sexual activity.

GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, and anal cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN) or anal intraepithelial neoplasia (AIN).

Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58.

Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.

Select safety information for GARDASIL 9

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL.

Because vaccines may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following HPV vaccination. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.

Safety and effectiveness of GARDASIL 9 have not been established in pregnant women.

The most common (‰¥10%) local and systemic adverse reactions in females were injection-site pain, swelling, erythema, and headache. The most common (‰¥10%) local and systemic reactions in males were injection-site pain, swelling, and erythema.

The duration of immunity of GARDASIL 9 has not been established.

Dosage and administration for GARDASIL 9

GARDASIL 9 should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh.

  • For individuals 9 through 14 years of age, GARDASIL 9 can be administered using a 2-dose or 3-dose schedule. For the 2-dose schedule, the second dose should be administered 6-12 months after the first dose. If the second dose is administered less than 5 months after the first dose, a third dose should be given at least 4 months after the second dose. For the 3-dose schedule, GARDASIL 9 should be administered at 0, 2 months, and 6 months.
  • For individuals 15 through 45 years of age, GARDASIL 9 is administered using a 3-dose schedule at 0, 2 months, and 6 months.

About HPV and HPV-related cancers and diseases

In the U.S., based upon modeled data, it is estimated that HPV will infect most sexually active males and females in their lifetime. According to the CDC, there are approximately 14 million new genital HPV infections in the U.S. each year, with roughly half occurring in people 25 years of age and older. For most people, HPV clears on its own, but for others who don’t clear the virus it could lead to cervical, vaginal, and vulvar cancers in women, and anal cancer and genital warts in men and women. The majority of these cancers and diseases are caused by the nine types of HPV covered by GARDASIL 9. Studies suggest that sexually active adults remain at risk for acquiring new HPV infections, and for men in particular, the rate of new infection remains relatively constant, irrespective of age. There is no way to know which people who have HPV will develop cancer or other health problems.

According to the American Cancer Society, the number of new anal cancer cases has been rising for many years. There is no routine screening recommended for the general population to reduce the risk of anal cancer. Approximately three out of four people get genital warts after having genital contact with someone who has them. Treatment of genital warts can be painful, and they can recur after treatment, especially in the first three months. Persistent HPV infection can also lead to abnormal Pap results that may require additional follow-up procedures.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimers disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the companys ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the companys patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys 2018 Annual Report on Form 10-K and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov).

Please see Prescribing Information for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) at https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf and Patient Information/Medication Guide for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) at https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_ppi.pdf.

Media:

Pamela Eisele

(267) 305-3558

Deb Wambold

(267) 305-064

Investors:

Teri Loxam

(908) 740-1986

Michael DeCarbo

(908) 740-1807

News

PG&E PSPS Oct. 26 10:00 PM Update: More Than 156,000 Customers Have Been Restored Since Monday Morning, With Essentially All Other Customers Expected to Have Power Back On by Tuesday Night

gbafNews28

Pacific Gas and Electric Company (PG&E) restored power Monday night by 10:00 PM to more than 156,000 of the approximately 345,000 customers impacted by the Public Safety Power Shutoff (PSPS) that started Sunday morning on Oct. 25. All remaining customersapproximately 189,000are expected to have power back on late Tuesday evening.

PG&E crews began restoring power to customers where no damage or hazards to electrical equipment were found during inspections that began as early as Monday morning in locations where the weather all clear was received. In areas where equipment was damaged by the severe wind event, crews worked safely and as quickly as possible to make the repairs and restore those customers.

Today, PG&E meteorologists issued a weather all clear for most of the areas impacted by this PSPS event. To fully restore service, PG&E crews will need to complete their patrols of over 17,000 miles of transmission and distribution lines for damage or hazards.

The patrol and inspection efforts include nearly 1,800 on-the-ground personnel, 65 helicopters and one airplane. Preliminary data shows at least 13 instances of weather-related damage and hazards in the PSPS-affected areas. Examples include downed lines and vegetation on power lines. If PG&E had not de-energized power lines, these types of damage could have caused wildfire ignitions.

PSPS Restoration

PG&E has restored 156,000 customers today and expects all remaining customers to have power back on late Tuesday evening. Restoration may be delayed for some customers if there is significant damage to individual lines, which could be caused by wind-blown branches and other debris.

The restoration process PG&E follows includes:

  1. Patrol “ PG&E crews look for potential weather-related damage to the lines, poles and towers. This is done by foot, vehicle and air.
  2. Repair “ Where equipment damage is found, PG&E crews isolate the damaged area from the rest of the system so other parts of the system can be energized.
  3. Restore “ Once the system is safe to energize, PG&E’s Control Center can complete the process and restore power to affected areas.
  4. Notify Customers “ Customers are notified that power has been restored.

For more information on the PSPS event, visit pge.com/pspsupdates.

Extreme Winds Recorded Across Service Area

Winds in de-energized areas due to PSPS were recorded as follows:

County

Max recorded sustained winds (mph)

Max recorded wind gusts (mph)

Sonoma

76

89

Napa

54

82

Contra Costa

55

74

Lake

57

71

Placer

42

71

Alameda

52

66

More Information on PG&E PSPS Events

PG&Es goal is to have essentially all customers affected by the PSPS who can receive power restored within 12 daylight hours of the weather All Clear for each affected area.

PG&E uses a PSPS only as the last resort to protect community and customer safety against wildfires, given dry and windy weather, dry vegetation and an elevated fire risk across portions of its service area.

PG&E will submit a report detailing damage from the severe weather to the California Public Utilities Commission within 10 days of the completion of the PSPS.

For more information on the PSPS event, visit pge.com/pspsupdates.

About PG&E

Pacific Gas and Electric Company, a subsidiary of PG&E Corporation (NYSE:PCG), is one of the largest combined natural gas and electric energy companies in the United States. Based in San Francisco, with more than 23,000 employees, the company delivers some of the nation’s cleanest energy to 16 million people in Northern and Central California. For more information, visit pge.com and pge.com/news.

Media Relations

415-973-5930

Continue Reading

News

EquitiesFirst Appoints Gordon Crosbie-Walsh Chief Executive Officer, Asia

gbafNews28

HONG KONG, Oct. 27, 2020 /PRNewswire/ — Equities First Holdings ("EquitiesFirst"), the global asset-backed financing company, today announced the appointment of Gordon Crosbie-Walsh as Chief Executive Officer, Asia with immediate effect. In his new role, Gordon will be tasked with managing EquitiesFirst’s operations throughout the Asia region with a focus on business development across Hong Kong, Singapore, Thailand, South Korea and Mainland China.

Equities First Holdings (“EquitiesFirst”) today announced the appointment of Gordon Crosbie-Walsh as Chief Executive Officer, Asia with immediate effect.
Equities First Holdings (“EquitiesFirst”) today announced the appointment of Gordon Crosbie-Walsh as Chief Executive Officer, Asia with immediate effect.

Gordon brings more than three decades of financial services experience to his new role, including chartered accounting, equity research, equity sales and investment banking. Prior to joining EquitiesFirst, Gordon led several investment banking businesses in Asia, including CM Financial and Jefferies Asia, where he was also Head, Equity Capital Markets. Prior to Jefferies, Gordon held a senior leadership role at JP Morgan’s Equity Capital Markets division. Before this role, Gordon spent more than a decade as Managing Director, Head of Equity Sales at Deutsche Bank and Salomon Smith Barney.

EquitiesFirst’s Executive Chairman and Chief Executive Officer, Al Christy Jr said today, "Gordon’s career track record makes him the ideal candidate to take our Asia business to the next level. We are in the progressive capital business and Gordon brings a deep understanding of the regional markets making him a natural fit for the Chief Executive role. Our innovative investment model overcomes the limitations of traditional financing where our partners receive non-recourse capital at very competitive terms in exchange for asset collateral."

Gordon Crosbie-Walsh said from Hong Kong today, "It is an honour to be appointed Chief Executive Officer at EquitiesFirst. I have always had respect for the firm and their unique investment model which makes us the best-fit solution for underserved asset owners seeking efficient capital. We seek mutually beneficial relationships that enable our partners to seize investment and business opportunities effectively and rapidly. I look forward to working with the team in Asia and our global leadership as we take EquitiesFirst to new levels of success and performance."

About Equities First Holdings

Equities First Holdings ("EquitiesFirst") is a global institutional investment company, whollyowned by American financier and entrepreneur Alexander Christy, Jr. The firm manages over USD1 billion of proprietary capital in a public equities portfolio. The firm’s core investment strategy is to manage a public equity portfolio. Its method of portfolio construction is based on equity-backed financing. Scaled worldwide, EquitiesFirst has provided progressive capital to hundreds of corporations, investors and other long-term shareholders.

The firm was incorporated in 2002 and is headquartered in Indianapolis, USA. EquitiesFirst maintains an international footprint of 12 offices, operating in all major financial markets. All subsidiaries are either licensed or registered with local financial regulators, including Hong Kong, the United Kingdom, Australia and Dubai.

EquitiesFirst is licensed by the Securities and Futures Commission of Hong Kong with CE number BFJ407 for the Regulated Activity of Dealing in Securities. www.equitiesfirst.com

©2020 Equities First Holdings Hong Kong Limited. All rights reserved.

Related Links :

http://www.equitiesfirst.com

Continue Reading

News

Arcc Spaces Launches Innovative ‘Agile Hybrid Solution’

gbafNews28

Concept designed to help businesses and individuals cope with Covid-19 remote working challenges

SINGAPORE, Oct. 27, 2020 /PRNewswire/ — Arcc Spaces, the leading shared workspace brand with 16 premium locations across Asia, today announces the launch of its new innovative ‘Agile Hybrid Solution’. The unique offering is provided under the Arcc Spaces Care+ Solutions package to help small and medium sized business (SMEs), multinational corporations (MNCs), start-ups, and entrepreneurs to cope with the new remote working situation resulting from Covid-19. The pandemic has forced some companies to downsize and establish remote working on a permanent basis, or at the very least until well into 2021. The new home office environment that many employees have found themselves in, however, is creating new challenges in terms of productivity, wellbeing and appropriate furniture to perform.

Arcc Spaces Care+ solutions offers 'On Demand Solution', 'Agile Hybrid Solution' and 'Enterprise Solution Powered By Design Studio' to cope with Covid-19 remote working challenges
Arcc Spaces Care+ solutions offers ‘On Demand Solution’, ‘Agile Hybrid Solution’ and ‘Enterprise Solution Powered By Design Studio’ to cope with Covid-19 remote working challenges

Arcc Spaces Care+ Solutions offers three solutions. ‘On Demand Solution’ provides passes ranging from five days to one month for members to access four centres located at One Marina Boulevard, 75 High Street, Suntec City and 99 Duxton Road to enjoy working at the shared space and premium office facilities. ‘Agile Hybrid Solution (AHS)’ is a tailor-made solution for individuals, SMEs and MNCs to cope with employee needs for remote working. Some employees face challenges when they work from home such as disruptive environments, poor connectivity and bad posture. AHS allows companies to sign up memberships for their employees to use the private suites, shared spaces and meeting rooms at Arcc Spaces’ four centres. Most importantly the solution comes with a European-made height-adjustable table and HAG Capisco chair delivered to employees’ homes by Arcc Spaces’ strategic business partner, Ecopex Furniture. Ecopex and Arcc Spaces are developing innovative solutions to the challenges of Covid-19, emphasizing sustainability through its use of refurbished products and its support of the circular economy. This helps boost employee productivity and comfort while working from home. So far, a global technology company, a US bank, and two real estate companies are already signed up for the new solution. In total, 30 individuals are enrolled in the programme at launch. Finally, ‘Enterprise Solution Powered By Design Studio’ offers corporate clients with tailor-made, personalised workplaces to meet their enterprise needs.

Matthew Chisholm, Chief Operating Officer of Arcc Spaces, said: "The launch of our ‘Agile Hybrid Solution’ represents a milestone in our thinking. Arcc Spaces has been in the market for over 20 years and has been evolving to meet individual and corporate needs. This solution extends our service from the flexible workplace to the home workplace. This new offering is a first step towards the future of work, where we leverage innovative valued-added bundles which solve for each individual and better understands their needs. The data we are collecting on behalf of our corporate clients will assist us to respond to ongoing changes in the workplace, ensuring we remain ahead of the curve in driving productivity, wellbeing and engagement for both individuals and the organisations they are part of.  

Henrik Meltesen, Founder and Owner of Ecopex Furniture, said: "Technology has empowered modern workers with enhanced mobility and connectivity to work from anywhere at anytime. Workstation ergonomics are a vital element in improving health and increasing productivity. In response to this, we have carefully selected and curated a range of workplace solutions to address the increase in remote collaboration. Arcc Spaces’ ‘Agile Hybrid Solution’ creates new value for its members, and increases customer loyalty and retention rates. Moreover, we are able to leverage customer feedback to improve our offerings and better serve market needs."

The on-demand five-day pass starts from SGD 188 and ‘Agile Hybrid Solution’ monthly fees starts from SGD 519. For details, please visit: https://discover.arccspaces.com/care-plus-package-singapore.

About Arcc Spaces

Arcc Spaces is a shared workspace brand with 16 locations across Asia that works with corporates to transform the way they work and drive innovation through a network of hospitality-led spaces. Headquartered in Singapore, Arcc Spaces has locations across Malaysia, Beijing, Shanghai and Hong Kong.  We provide access to a collection of beautifully designed business hubs, lounges and labs grounded in landmark projects across the world’s gateway cities to empower today’s leaders to meet, collaborate, learn and access talents and opportunities. Arcc Spaces is a part of the Arcc Holdings, a transformative real estate and hospitality company that develops and operates a range of concepts in the areas of ‘Work, Live and Play’. For more information, please visit https://www.arccspaces.com

 

Related Links :

https://www.arccspaces.com/

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News60 mins ago

PG&E PSPS Oct. 26 10:00 PM Update: More Than 156,000 Customers Have Been Restored Since Monday Morning, With Essentially All Other Customers Expected to Have Power Back On by Tuesday Night

Pacific Gas and Electric Company (PG&E) restored power Monday night by 10:00 PM to more than 156,000 of the approximately...

gbafNews28 gbafNews28
News1 hour ago

Asia Trading Summit: One of the world’s largest+ global forex and CFD brokers, Pepperstone moves its events online, partners with APAC influencers.

MELBOURNE, Australia, Oct. 27, 2020 /PRNewswire/ — Pepperstone, built on an uncompromising level of service for all its clients and...

gbafNews28 gbafNews28
News1 hour ago

Arcc Spaces Launches Innovative ‘Agile Hybrid Solution’

Concept designed to help businesses and individuals cope with Covid-19 remote working challenges SINGAPORE, Oct. 27, 2020 /PRNewswire/ — Arcc...

gbafNews28 gbafNews28
News1 hour ago

EquitiesFirst Appoints Gordon Crosbie-Walsh Chief Executive Officer, Asia

HONG KONG, Oct. 27, 2020 /PRNewswire/ — Equities First Holdings ("EquitiesFirst"), the global asset-backed financing company, today announced the appointment of...

gbafNews28 gbafNews28
News1 hour ago

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and...

gbafNews28 gbafNews28
News1 hour ago

Relocation Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024

The Relocation Services market will register an incremental spend of about USD 4 billion, growing at a CAGR of 3.01%...

gbafNews28 gbafNews28
News1 hour ago

Insights & Forecast With Potential Impact of COVID-19 – Global MEMS Microphone Market 2020-2024 | Increased Penetration of MEMS Technology in Hearing Aids to Boost Market Growth | Technavio

The MEMS microphone market is expected to grow by USD 683.84 million during 2020-2024, according to Technavio. The report offers...

gbafNews28 gbafNews28
News1 hour ago

As Tech CEOs Face Senate Commerce Committee Hearing, New Survey From the Internet Society Shows Americans Don’t Trust Politicians to Regulate the Internet

A new online survey of US Internet users conducted by YouGov on behalf of the Internet Society, shows the majority...

gbafNews28 gbafNews28
News2 hours ago

Plastic Welding Equipment Market Procurement Intelligence Report With COVID-19 Impact Analysis | Global Forecasts, 2020-2024

The Plastic Welding Equipment market will register an incremental spend of about USD 1 billion, growing at a CAGR of...

gbafNews28 gbafNews28
News2 hours ago

COVID-19 Impact: Plating on Plastics (POP) Market Will Accelerate at a CAGR of About 7% Through 2020-2024 | Increasing Use of Acrylonitrile Butadiene Styrene (ABS) to Boost Growth | Technavio

The plating on plastics market is expected to grow by USD 275.75 million during 2020-2024, according to Technavio. The report...